Infliximab 5 mg/kg may leads to higher clinical remission at week 26 compared with purine analogues (low certainty).
Infliximab 5 mg/kg may leads to higher clinical response at week 26 compared with purine analogues (low certainty).
Infliximab 5 mg/kg showed no clear difference in withdrawals due to adverse events compared with purine analogues (low certainty).
It is very uncertain whether infliximab 5 mg/kg changes clinical remission defined as CDAI < 150 at week 4 compared with infliximab 10 mg/kg (very low certainty).
It is very uncertain whether infliximab 5 mg/kg changes clinical response defined as reduction in CDAI by 70 points at week 4 compared with infliximab 10 mg/kg (very low certainty).
The review found no eligible studies for this question.
It is very uncertain whether infliximab 5 mg/kg changes clinical remission defined as absence of any draining fistulas at ≥… compared with infliximab 10 mg/kg (very low certainty).
It is very uncertain whether infliximab 5 mg/kg changes clinical response defined as reduction of 50% in the number of… compared with infliximab 10 mg/kg (very low certainty).
It is very uncertain whether infliximab 5 mg/kg changes clinical remission at week 4 compared with infliximab 20 mg/kg (very low certainty).
It is very uncertain whether infliximab 5 mg/kg changes clinical response as defined by the studies week 4 compared with infliximab 20 mg/kg (very low certainty).
The review found no eligible studies for this question.
Infliximab 5 mg/kg showed no clear difference in clinical remission defined as CDAI < 150 at week 6 compared with CT‐P13 biosimilar 5 mg/kg (low certainty).
Infliximab 5 mg/kg showed no clear difference in clinical response defined by reduction of CDAI score by ≥ 100 at… compared with CT‐P13 biosimilar 5 mg/kg (low certainty).
Infliximab 5 mg/kg showed no clear difference in withdrawals due to adverse events compared with CT‐P13 biosimilar 5 mg/kg (low certainty).
It is very uncertain whether infliximab 10 mg/kg changes clinical remission defined as CDAI < 150 at week 4 compared with infliximab 20 mg/kg (very low certainty).
It is very uncertain whether infliximab 10 mg/kg changes clinical response defined by reduction of CDAI score by ≥ 70 at week 4 compared with infliximab 20 mg/kg (very low certainty).
The review found no eligible studies for this question.
Infliximab 5–10 mg/kg may leads to higher clinical remission defined as CDAI < 150 at week 4 compared with placebo (low certainty).
Infliximab 5–10 mg/kg may leads to higher clinical response defined as improvement in the scores on the CDAI… compared with placebo (low certainty).
The review found no eligible studies for this question.